SAN
DIEGO, Aug. 21, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage
biotechnology company, today announced a presentation of two-year
follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1
study evaluating adagrasib in in patients with non-small cell lung
cancer (NSCLC) harboring a KRASG12C mutation.
Findings will be presented at the 2023 World Conference on Lung
Cancer during the press conference on September 10th 10:35 a.m. – 10:40
a.m. SGT / September
9th 7:35 p.m. –
7:40 p.m. PT and as a mini-oral
presentation in the "Targeted Therapy: KRAS and Beyond" session
occurring on September
10th at 4:22 p.m.
SGT / 1:22 a.m. PT.
About Mirati Therapeutics, Inc.®
Mirati
Therapeutics, Inc. is a commercial stage biotechnology company
whose mission is to discover, design and deliver breakthrough
therapies to transform the lives of patients with cancer and their
loved ones. The company is relentlessly focused on bringing forward
therapies that address areas of high unmet need, including lung
cancer, and advancing a pipeline of novel therapeutics targeting
the genetic and immunological drivers of cancer. Unified for
patients, Mirati's vision is to unlock the science behind the
promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us
on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes
forward-looking statements regarding Mirati's business, financial
guidance and the therapeutic and commercial potential of
KRAZATI® (adagrasib), MRTX1719 (MTA-cooperative PRMT5
inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective
KRASG12D inhibitor), Mirati's technologies and Mirati's other
products in development. Any statement describing Mirati's goals,
expectations, intentions or beliefs, financial or other
projections, is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, including those inherent in the
process of discovering, developing and commercializing medicines
that are safe and effective for use as human therapeutics, and in
the endeavor of building a business around such medicines. Mirati's
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements. Although Mirati's forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Mirati. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning
Mirati's programs are described in additional detail in Mirati's
annual report on Form 10-K, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission and available at
the SEC's Internet site (www.sec.gov). These forward-looking
statements are made as of the date of this press release, and
Mirati assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
Mirati Contacts
Investor Relations: ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-to-present-pooled-clinical-data-from-adagrasibs-krystal-1-study-demonstrating-overall-survival-results-at-two-years-of-follow-up-at-2023-world-conference-on-lung-cancer-301905906.html
SOURCE Mirati Therapeutics, Inc.